Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, komentáře
Grantová podpora
110078/Z/15/Z
Wellcome Trust - United Kingdom
PubMed
34666894
DOI
10.1016/j.jid.2021.09.005
PII: S0022-202X(21)02269-7
Knihovny.cz E-zdroje
- MeSH
- imunita MeSH
- imunoterapie MeSH
- lidé MeSH
- melanom * farmakoterapie MeSH
- telomerasa * MeSH
- Th1 buňky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
- Názvy látek
- telomerasa * MeSH
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.
Cancer Research UK Manchester Institute The University of Manchester Manchester United Kingdom
Department of Dermatology Instituto Valenciano de Oncologia Valencia Spain
Citace poskytuje Crossref.org
